- IN₹5.21bn
- IN₹5.71bn
- IN₹1.11bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.64 | ||
| Price to Tang. Book | 9.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.4 | ||
| EV to EBITDA | 34.91 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.43% | ||
| Return on Equity | 1.4% | ||
| Operating Margin | 4.45% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 614.89 | 862.51 | 1,940.85 | 930.73 | 1,111.95 | n/a | n/a | 9.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lyka Labs Limited is an India-based company that is engaged in the business of pharmaceutical and related activities, including research. The Company is focused on lyophilization - formulations/bulk sterile active pharmaceutical ingredients (APIs), and new product development including novel drug delivery systems in both topical preparation and lyophilized products. The Company manufactures pharmaceutical products, such as dry powder, liquid injections, lyophilized injections, ointment/creams and lotions, and external preparations for several international markets and the domestic market. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, anti-fungal, anti-malarial, anti-bacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
Directors
- Kunal Gandhi CEO
- Yogesh Shah CFO
- Piyush Hindia CCO
- Nehal Gandhi NED (62)
- Sandeep Parikh IND (54)
- Vinod Shanbhag IND
- Dhara Shah NID
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- December 29th, 1976
- Public Since
- February 9th, 1995
- No. of Shareholders
- 26,143
- No. of Employees
- 423
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 35,690,000
- Address
- 101 - Shiv Shakti Industrial Estate, MUMBAI, 400036
- Web
- http://www.lykalabs.com/
- Phone
- +91 2266112200
- Auditors
- D. Kothary & Co.
Upcoming Events for LYKALABS
Q3 2025 Lyka Labs Ltd Earnings Release
Similar to LYKALABS
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Lyka Labs share price?
As of Today at 21:51 UTC, shares in Lyka Labs are trading at IN₹145.87. This share price information is delayed by 15 minutes.
How has the Lyka Labs share price performed this year?
Shares in Lyka Labs last closed at IN₹145.87 and the price had moved by +26.24% over the past 365 days. In terms of relative price strength the Lyka Labs share price has underperformed the S&P BSE 100 Index by -7.47% over the past year.
What are the analyst and broker recommendations for Lyka Labs?
There is no consensus recommendation for this security.
Find out moreWhat is the Lyka Labs dividend yield?
Lyka Labs does not currently pay a dividend.
Does Lyka Labs pay a dividend?
Lyka Labs does not currently pay a dividend.
When does Lyka Labs next pay dividends?
Lyka Labs does not currently pay a dividend.
How do I buy Lyka Labs shares?
To buy shares in Lyka Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lyka Labs?
As of the previous close price of IN₹145.87, shares in Lyka Labs had a market capitalisation of IN₹5.21bn.
Where are Lyka Labs shares listed?
Here are the trading details for Lyka Labs:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: LYKALABS
What kind of share is Lyka Labs?
Based on an overall assessment of its quality, value and momentum Lyka Labs is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lyka Labs share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Lyka Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lyka Labs. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +7.43%.
As of the last closing price of IN₹145.87, shares in Lyka Labs were trading +18.33% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lyka Labs PE Ratio?
The Lyka Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹145.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lyka Labs?
Lyka Labs' management team is headed by:
- Kunal Gandhi - CEO
- Yogesh Shah - CFO
- Piyush Hindia - CCO
- Nehal Gandhi - NED
- Sandeep Parikh - IND
- Vinod Shanbhag - IND
- Dhara Shah - NID